EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy and Safety of 12‐Week Coblopasvir/Sofosbuvir Regimen for Hepatitis C in Northwest China: A Multi‐Center Prospective Study

Lu Yan, Maimaitijiang Wubuliaishan, Xiaoni Kou, Maimaitiaili Tuerxun, Mingbo Yang, Fanpu Ji iD, Yingli He, Jiuping Wang, Longdong Zhu, Xiaohong Gao, Fuchun Jing iD, Xiangchun Ding iD und 3 weitere

Journal of Medical Virology · 2026

DOI: 10.1002/jmv.70978 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Lu Yan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Sofosbuvir, Antiviral Agents, Hepatitis C, Chronic. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To assess the sustained virologic response (SVR12) and safety profile of 12‐week coblopasvir/sofosbuvir (COB/SOF) therapy in hepatitis C virus (HCV)‐infected patients across genotypes in Northwest China. This prospective cohort study (2023–2024) enrolled HCV patients from 12 clinical centers in Northwest China, adhering to the China Hepatitis C Prevention Guidelines (2022). Participants received daily oral coblopasvir (60 mg) and sofosbuvir (400 mg) for 12 weeks. Key endpoints included HCV RNA quantification, genotype distribution, liver/kidney biomarkers, ultrasound findings, and liver stiffness measurements at baseline, end‐of‐treatment (EOT), and 12 weeks post‐treatment (SVR12). Cirrhosis was defined by ultrasound and transient elastography (> 14.6 kPa). Of 209 initiators, 170 completed treatment (median age 52.5; 57.1% female), including 21 cirrhotic patients. Genotype distribution showed predominance of 1b (38.2%), 2a (31.2%), and 3a (12.4%), with rare 6a (0.6%) and untypable (2.4%). The EOT virologic clearance rate reached 98.8% (168/170), with SVR12 of 99.4% (128/129). Significant improvements occurred in liver biochemical indicators: ALT ( p < 0.001), AST ( p < 0.001), GGT ( p < 0.001), TBil ( p = 0.04 at SVR12). RBC increased ( p = 0.04 at EOT; p = 0.00358 at SVR12). No renal impairment was observed (Cr, UA, UREA p > 0.05). The regimen demonstrated excellent tolerability with no severe adverse events. The COB/SOF combination achieved high SVR12 rates (> 99%) across diverse HCV genotypes in Northwest China, including cirrhotic patients, with concurrent liver function recovery and stable renal parameters. These real‐world data support its first‐line application in resource‐limited regions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SofosbuvirAntiviral AgentsHepatitis C, ChronicHumansFemaleProspective StudiesMaleChinaHepacivirusSustained Virologic ResponseGenotypeMiddle AgedAdultTreatment OutcomeDrug Therapy, CombinationLiver CirrhosisAged

Stichwörter der Autor:innen

coblopasvirefficacypangenotypic regimensafetysofosbuvirsustained virological response

Substanzen

SofosbuvirAntiviral Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Department of Liver Disease, Hotan Regional Infectious Diseases Hospital, Hotan, Xinjiang, China.
  • Department of Hepatology, Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi, China.
  • Department of Infection, Kashgar First People's Hospital, Kashgar, Xinjiang, China.
  • Hepatology Department of TCM, Xi'an No.8 Hospital, Xi'an, Shaanxi, China.
  • Department of Hepatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

ORCID-Profile: Fanpu Ji, Fuchun Jing, Xiangchun Ding, Ye Zhang, Hong Jiang

Zitieren

APA

Yan, L., Wubuliaishan, M., Kou, X., Tuerxun, M., Yang, M., Ji, F., He, Y., Wang, J., Zhu, L., Gao, X., Jing, F., Ding, X., Du, H., Zhang, Y., & Jiang, H. (2026). Efficacy and Safety of 12‐Week Coblopasvir/Sofosbuvir Regimen for Hepatitis C in Northwest China: A Multi‐Center Prospective Study. Journal of Medical Virology. https://doi.org/10.1002/jmv.70978

Vancouver

Yan L, Wubuliaishan M, Kou X, Tuerxun M, Yang M, Ji F, et al. Efficacy and Safety of 12‐Week Coblopasvir/Sofosbuvir Regimen for Hepatitis C in Northwest China: A Multi‐Center Prospective Study. Journal of Medical Virology. 2026. doi:10.1002/jmv.70978

BibTeX
@article{Yan2026,
  author = {Yan, Lu and Wubuliaishan, Maimaitijiang and Kou, Xiaoni and Tuerxun, Maimaitiaili and Yang, Mingbo and Ji, Fanpu and He, Yingli and Wang, Jiuping and Zhu, Longdong and Gao, Xiaohong and Jing, Fuchun and Ding, Xiangchun and Du, Hong and Zhang, Ye and Jiang, Hong},
  title = {Efficacy and Safety of 12‐Week Coblopasvir/Sofosbuvir Regimen for Hepatitis C in Northwest China: A Multi‐Center Prospective Study},
  journal = {Journal of Medical Virology},
  year = {2026},
  doi = {10.1002/jmv.70978}
}
Kostenlos starten →